SCHEMBL29493334

SCHEMBL29493334

C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 2/20 0.61
▸ KDM4E B2RXH2 2/20 0.59
▸ POLB P06746 2/20 0.59
▸ APAF1 O14727 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ MMP9 P14780 2/20 0.58
▸ MMP8 P22894 2/20 0.58
▸ MEN1 O00255 1/20 0.57
▸ HTT P42858 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ ECE1 P42892 7/20 0.57
▸ P2RY14 Q15391 1/20 0.57
▸ ALOX15 P16050 1/20 0.56
▸ OPRM1 P35372 1/20 0.55
▸ OPRD1 P41143 1/20 0.55
▸ MMP1 P03956 1/20 0.55
▸ MMP3 P08254 1/20 0.55
▸ GHSR Q92847 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9822619 1.00 ACE (0.61) ACEKDM4EPOLBAPAF1MAPT
SCHEMBL31571452 0.94 MMP2 (0.58) ACEKDM4EPOLBAPAF1MAPT
SCHEMBL3855087 0.90 ACE (0.56) ACEKDM4EPOLBAPAF1MAPT
SCHEMBL3855086 0.90 ACE (0.56) ACEKDM4EPOLBAPAF1MAPT
SCHEMBL30051742 0.90 ACE (0.68) ACEECE1P2RY14ALOX15
SCHEMBL30051401 0.89 ACE (0.59) ACEKDM4EPOLBAPAF1MAPT
SCHEMBL9822645 0.89 ECE1 (0.68) ACEMMP9MMP8ECE1MMP1
SCHEMBL30051404 0.89 ECE1 (0.68) ACEMMP9MMP8ECE1MMP1
SCHEMBL30834730 0.89 ACE (0.58) ACEKDM4EPOLBAPAF1MAPT
SCHEMBL9822708 0.88 ACE (0.65) ACEKDM4EPOLBAPAF1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 — — US disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 — — US disclosed
CN-113735968-A9 Method for measuring titer of swine transmissible gastroenteritis virus N protein antibody 山东畜牧兽医职业学院 2022-04-29 — — CN disclosed
CN-113740528-A9 Swine transmissible gastroenteritis virus antibody detection kit 山东畜牧兽医职业学院 2022-04-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP ACE 1190/4885KDM4E 1136/4885POLB 1787/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD ACE 486/4885KDM4E 4697/4885POLB 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback